-+ 0.00%
-+ 0.00%
-+ 0.00%

Exelixis: A Strong Contender in the Cancer Drug Market

The Motley Fool·03/31/2026 23:20:00
Listen to the news

Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 11, 2026. The video was published on March 31, 2026.

Anand Chokkavelu has no position in any of the stocks mentioned. Karl Thiel has positions in Exelixis. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy.